Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...1819202122232425262728...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    EGFR-targeted mesenchymal stem cells for enhanced tumor retention and inhibition (Section 19; Poster Board #24) -  Mar 14, 2023 - Abstract #AACR2023AACR_2414;    
    Biodistribution studies revealed a sixfold higher retention of functionalized MSCs when compared to unfunctionalized MSCs. These results demonstrate the potential for improved tumor targeting with EGFR-targeted MSCs.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    ADAM17 knockout NK or CAR NK cells augment antibody dependent cellular cytotoxicity (ADCC) and anti-tumor activity (Section 37; Poster Board #5) -  Mar 14, 2023 - Abstract #AACR2023AACR_2271;    
    Similarly, ADAM17 KO NK cells and ADAM17 KO CD70 CAR NK cells also showed enhanced cytotoxicity against 786-O tumor cells in the presence of anti-EGFR antibody, cetuximab...Taken together, we show ADAM17 KO NK or ADAM17 KO CAR NK cells demonstrate improved ADCC and ADAM17 KO can enhance in vivo anti-tumor activity of CISH/CBLB KO CD70 CAR NK cells against relevant tumor models. These data support the further exploration of ADAM17 gene knockout NK cells for clinical application and to improve efficacy of therapeutic antibodies in combination with adoptive transfer of engineered NK cells.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Are we ready for deintensification in human papillomavirus-positive oropharyngeal carcinomas? (Pubmed Central) -  Mar 14, 2023   
    Promising selection criteria included either static baseline features or kinetic characteristics of clinical-biological parameters. Practice-changing trials remain elusive, and the search continues to attempt optimization of the therapeutic ratio for these patients.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, RSL3 / Stanford University
    Journal:  Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. (Pubmed Central) -  Mar 11, 2023   
    This is illustrated by the reduction in cell survival, the alteration of cell metabolism associated with mitochondrial dysfunction and the initiation of ferroptosis characterized by lipid peroxidation, iron accumulation and the loss of GPX4. Combining ferroptosis inducers (RSL3 and metformin) with CTX drastically reduces the survival of HNSCC cells but also HNSCC patient-derived tumoroids; (4) The loss of EREG might be considered in clinical settings as a predictive biomarker for patients that might undergo ferroptosis in response to CTX and that might benefit the most from the combination of ferroptosis inducers and CTX.
  • ||||||||||  azenosertib (ZN-c3) / Zentalis Pharma
    Enrollment open, Combination therapy, Metastases:  ZN-c3 in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 10, 2023   
    P1/2,  N=82, Recruiting, 
    Combining ferroptosis inducers (RSL3 and metformin) with CTX drastically reduces the survival of HNSCC cells but also HNSCC patient-derived tumoroids; (4) The loss of EREG might be considered in clinical settings as a predictive biomarker for patients that might undergo ferroptosis in response to CTX and that might benefit the most from the combination of ferroptosis inducers and CTX. Not yet recruiting --> Recruiting
  • ||||||||||  monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
    Enrollment closed, Trial completion date, IO biomarker, Metastases:  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) -  Mar 9, 2023   
    P1/2,  N=383, Active, not recruiting, 
    The use of molecularly targeted agents in the neoadjuvant setting for locally advanced rectal cancer has an acceptable prognosis. Completed --> Active, not recruiting | Trial completion date: Oct 2021 --> Jun 2023
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Cost-Effectiveness of Pembrolizumab for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Colombia () -  Mar 9, 2023 - Abstract #ISPOR2023ISPOR_710;    
    This study evaluated the cost-effectiveness of pembrolizumab as combination therapy with platinum-based therapies (cisplatin or carboplatin) plus 5-FU in the CPS?1 population versus cetuximab + platinum + 5-FU from a third payer perspective in Colombia... Pembrolizumab in combination with chemotherapy offers substantial survival and QALY gains for patients with R/M HNSCC with PD-L1 expression of CPS?1 at small additional costs, making it a cost-effective treatment versus cetuximab + platinum + 5-FU in Colombia.
  • ||||||||||  etokimab (ANB020) / AnaptysBio, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    EGF is an important modulator of the release of the alarmin IL-33 by human keratinocytes () -  Mar 4, 2023 - Abstract #ISID2023ISID_1243;    
    The EGFR pathway is an important modulator of IL-33 release. A better understanding of the cellular events that leading to modulation of the alarmin IL-33 by EGF may provide novel therapeutic targets in atopic dermatitis.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats. (Pubmed Central) -  Mar 2, 2023   
    Herein, we describe the generation of potent NK cell engagers (NKCEs) based on single domain antibodies (sdAbs) specific for NKp46 harboring the humanized Fab version of Cetuximab for tumor targeting...By this means, killing capacities were further improved significantly. Hence, NKp46-specific sdAbs are versatile building blocks for the construction of different NKCE formats.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases:  Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review. (Pubmed Central) -  Mar 2, 2023   
    This article examines molecular markers that can predict colorectal cancer prognosis. Although treatment with monoclonal antibodies has demonstrated efficacy in terms of life-years gained and progression-free survival, the most cost-effective treatment among monoclonal antibodies remains controversial; however, most of the studies that compared a monoclonal antibody
  • ||||||||||  PF-07284892 / Pfizer
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 2, 2023   
    P1,  N=196, Recruiting, 
    Further prospective trials would be needed to confirm our results. Trial completion date: Feb 2027 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Apr 2025
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Trial completion date, Metastases:  PembroRad: Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (clinicaltrials.gov) -  Feb 28, 2023   
    P2,  N=133, Completed, 
    A comparison of cetuximab, PARPi and combination applications showed the superiority of combined applications over single applications in all cell kinetic parameters used. Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Oct 2022
  • ||||||||||  olomorasib (LY3537982) / Eli Lilly
    Trial completion date, Trial primary completion date, Metastases:  KEYNOTE E27: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (clinicaltrials.gov) -  Feb 27, 2023   
    P1a/1b,  N=400, Recruiting, 
    And they may be more sensitive to some chemotherapies but less to cetuximab. Trial completion date: Nov 2023 --> Sep 2025 | Trial primary completion date: Nov 2023 --> Sep 2025
  • ||||||||||  utomilumab (PF-05082566) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) -  Feb 27, 2023   
    P1,  N=42, Active, not recruiting, 
    Trial completion date: Oct 2022 --> Apr 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023